Spanish Drug Move To Boost Health Service Funds

18 November 1997

Spain's government has decided to give the national health servicebudget a boost by reducing the list of free drugs, ie drugs which are fully reimbursed by the social security system. It also said that the only possible alternative to spending increases is for a greater level of patient participation through contributing to the cost of medicines.

The total number of drugs to be excluded from the 100% reimbursement list is reportedly 500, and their exclusion, in government eyes, will add badly-needed funds to the estimated 165 billion pesetas ($1.13 billion) required to boost the health budget. However, strong opposition to the move is expected from the unions (not to mention the pharmaceutical industry), and government sources themselves admit the decision not to subsidize certain drug products has not been easy.

Overall, the state pays 60% of the public's drugs bill and 100% of that of pensioners. The secretary general of the CiU union, Pere Esteve, said the reduction in free medicines would damage the drug industry and was not a good idea either politically or technically. In turn, the CiU's comments have provoked criticism from ministers. The Minister for Public Administration, Mariona Rajoy, attacked "the voices calling for an increase in health spending."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight